This stock is a great choice for cautious and aggressive investors.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.

Stéphane Bancel, Moderna’s founding chief executive, has sold his six-level Beacon Hill townhouse after owning in the ...